Aeglea BioTherapeutics Q2 EPS $(2.27) Misses $(0.15) Estimate, Sales $688.00K Beat $200.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Aeglea BioTherapeutics reported Q2 losses of $(2.27) per share, missing the analyst consensus estimate of $(0.15) by 1413.33%. This is a 740.74% decrease from the same period last year. However, the company's quarterly sales of $688.00 thousand beat the analyst consensus estimate of $200.00 thousand by 244.00%, a 10.08% increase from last year.
August 11, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aeglea BioTherapeutics reported a significant miss on its Q2 EPS, but beat sales estimates. This mixed result could lead to uncertainty in the market.
Aeglea BioTherapeutics reported a significant miss on its Q2 EPS, which is a key measure of profitability. This could negatively impact investor sentiment. However, the company beat sales estimates, which could offset some of the negative sentiment. The mixed results could lead to uncertainty in the market, making it difficult to predict the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100